Prevalence of vitamin D deficiency in women from southern Brazil and association with vitamin D-binding protein levels and GC-DBP gene polymorphisms

Betânia Rodrigues Santos1,2, Nathália Cruz Costa1,2, Thais Rasia Silva1, Karen Oppermann3, José Antonio Magalhães4, Gislaine Casanova1,4, Poli Mara Spritzer1,2*

1 Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, 2 Laboratory of Molecular Endocrinology, Department of Physiology, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, 3 Medical School, Universidade de Passo Fundo and Hospital São Vicente de Paulo, Passo Fundo, Rio Grande do Sul, Brazil, 4 Division of Gynecology and Obstetrics, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil

* spritzer@ufrgs.br

Abstract

Vitamin D deficiency is highly prevalent worldwide, and vitamin D-binding protein (DBP) a major regulator of serum vitamin D levels. The rs4588 and rs7041 polymorphisms of the GC gene constitute the genetic basis of the three major isoforms of circulating DBP (GC1s, GC1f, and GC2), while the rs2282679 variant is located in an important regulatory region of the GC gene. The aim of this study was to assess the prevalence of 25-hydroxyvitamin D [25(OH)D] deficiency and to ascertain whether it is associated with DBP levels and with GC gene variants. Biorepository samples of 443 women aged 20 to 72 years, with no evidence of clinical disease, were analyzed. Circulating levels of 25(OH)D were considered sufficient if ≥20 ng/mL and deficient if <20 ng/mL. Genotype analysis was performed by RT-PCR. Mean age was 53.4±9.4 years; mean BMI was 27.8±5.8 kg/m². The overall sample had mean 25(OH)D levels of 22.8±8.3 ng/mL; 39.7% of participants had deficient circulating 25(OH)D levels. Higher prevalence ratios (PR) of 25(OH)D deficiency were found for the CC genotype of rs2282679 (PR 1.74; 95%CI 1.30 to 2.24; p<0.001), GC2 isoform (PR 1.66; 95%CI 1.17 to 2.38; p = 0.005), time since menopause (PR 1.02; 95%CI 1.003 to 1.03, p = 0.016), and HOMA-IR (PR 1.02; 95%CI 1.01 to 1.03, p = 0.004). DBP levels (per 30 μg/mL increase in DBP) were associated with lower PR for 25(OH)D deficiency (PR 0.89; 95%CI 0.80;0.99; p = 0.027). Except for HOMA-IR, these prevalence ratios remained significant after adjustment for age and BMI. In conclusion, the rs2282679 polymorphism and the GC2 isoform of DBP were associated with lower serum DBP levels and with susceptibility to 25(OH)D deficiency in Brazilian women with no evidence of clinical disease.
Introduction

Vitamin D deficiency is highly prevalent worldwide [1, 2] and has been regarded as a public health issue [3]. As a fat-soluble hormone, vitamin D is essential for the maintenance of calcium homeostasis, and has also been associated with hypertension, diabetes, the metabolic syndrome, cancer, autoimmune diseases, and infection, among other conditions [2, 4, 5].

Vitamin D-binding protein (DBP) is a member of the albumin and alpha-fetoprotein gene family encoded by the GC vitamin D binding protein gene (gene ID: 2638); it is produced in the liver, and its synthesis is regulated by estrogens. DBP is one of several regulators of serum vitamin D levels, with around 85–90% of the circulating vitamin D pool being bound to DBP [6, 7]. Total vitamin D correlates positively with DBP concentrations [8, 9].

Two well-studied single nucleotide polymorphisms (SNPs) of the GC gene, rs4588 and rs7041, form the molecular basis for the three major isoforms of circulating DBP (GC1f, GC1s, and GC2). These isoforms have different binding affinity for vitamin D [7] as well as different glycosylation patterns [10]. rs4588 and rs7041 have been associated with DBP concentrations [8, 11–14] and vitamin D levels [12, 15–18] in various populations. Another GC gene variant is the rs2282679 polymorphism, located at the 3' untranslated region (3' UTR) of the GC gene, which is involved in the modulation of gene expression and reportedly associated with vitamin D levels [19, 20].

Given this context, the aim of the present study was to assess circulating 25-hydroxyvitamin D [25(OH)D] and serum DBP levels and ascertain whether an association exists between the rs4588, rs7041, and rs2282679 polymorphisms of the GC gene and the presence of vitamin D deficiency in pre-, peri-, and postmenopausal women from southern Brazil.

Materials and methods

Study design and participants

This is a cross-sectional study of biorepository samples collected from 443 women aged 20 to 72 years, with no evidence of clinical disease, living in southern Brazil (30th parallel South). These women were prospectively recruited and participated in studies conducted at our research center from 2005 to 2012 [21–24]. Eighty percent of women were Caucasian and the remaining were of mixed African and European ancestry.

Serum samples had been previously collected and stored in aliquots at -80˚C for use in laboratory tests. An additional blood sample was collected from each participant in EDTA tubes or on FTA Elute cards (GE Healthcare, Buckinghamshire, UK) for DNA extraction and polymorphism genotyping. Menopause status was ascertained based on the characteristics of menses or time since amenorrhea: premenopause was defined as usual menstrual frequency or flow; perimenopause was defined as changes in menstrual frequency; and postmenopause was defined as 12 or more months of amenorrhea and/or follicle-stimulating hormone (FSH) levels ≥35 mIU/mL occurring after 40 years of age [25]. Women who had undergone hysterectomy and/or bilateral oophorectomy were excluded. Circulating levels of 25(OH)D were considered sufficient if ≥20 ng/mL and deficient if <20 ng/mL. The study protocol was approved by the Ethics Committee at Hospital de Clinicas de Porto Alegre (project 17–0226), and written informed consent was obtained from all subjects at the time of recruitment.

Study protocol

As reported elsewhere [21–24], a physical examination was performed and blood pressure, weight, height, and waist circumference (WC) were measured. The body mass index (BMI) was calculated as weight in kg divided by the height in m squared (kg/m²). The metabolic
syndrome and cutoff points for its isolated components were defined as per the Joint Scientific Statement [26]. Data on calcium and vitamin D supplementation and hormone therapy were collected at the time of recruitment.

**Laboratory parameters**

All samples were obtained between 8:00AM and 10:00AM. Blood samples were drawn after a 12-h overnight fast for determination of laboratory analyses. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and triglycerides were determined by enzymatic colorimetric methods (Bayer 1800 Advia System, Mannheim, Germany), with intra- and inter-assay coefficients of variation (CV) <3%. Low-density lipoprotein cholesterol (LDL-c) was calculated using the Friedewald formula [27]. The hexokinase method (Advia 1800, Mannheim, Germany) was used for glucose determination, with intra- and inter-assay CVs <3.4%. Serum insulin levels were measured by electrochemiluminescence immunoassay (ECLIA; Roche Diagnostics, Mannheim, Germany), with sensitivity of 0.200 μIU/mL and intra- and inter-assay CVs of 2.0% and 4.3% respectively. The homeostasis model assessment of insulin resistance index (HOMA-IR) was calculated by multiplying insulin (μIU/mL) by glucose (mmol/L) and dividing this product by 22.5 [28]. Estradiol was measured by electrochemiluminescence (Roche Diagnostics, Mannheim, Germany), with sensitivity of 5.0 pg/mL and intra- and inter-assay CVs of 5.7% and 6.4%, respectively. Individual results below the limit of sensitivity were considered equal to 5.0 pg/mL for purposes of statistical analysis. Levels of 25(OH)D were measured by chemiluminescence (Abbott Architect, IL, USA) with sensitivity of 1.6 ng/mL and intra- and inter-assay CVs of ≤5.1% and ≤7.1%, respectively. DBP was measured by commercial enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, USA), performed in accordance with the manufacturer’s instructions, with sensitivity of 0.180 ng/mL and intra- and inter-assay CVs of ≤2.2% and ≤6.5%, respectively. Serum albumin was measured using an automated colorimetric method (Vitros, São Paulo, Brazil). Free and bioavailable 25(OH)D levels were calculated using equations provided by Powe et al. [29], which in turn were adapted from the equations developed by Vermeulen et al. for calculation of free testosterone [30] and based on the concentration of total testosterone, sex hormone-binding globulin (SHBG), and albumin. The affinity binding constants for 25(OH)D with DBP and albumin were 7×10⁸ M⁻¹ and 6×10⁵ M⁻¹, respectively, as previously measured by Bikle et al. by centrifugal ultrafiltration dialysis [31]. Parathyroid hormone (PTH) and calcium levels were measured by chemiluminescent microparticle immunoassay (CMIA) (Abbott Architect, Wiesbaden, Germany) and the O-cresolphthalein colorimetric (Advia 1800, Mannheim, Germany) method respectively.

**Genotype analysis**

Genomic DNA was extracted from peripheral blood leukocytes [32] or from the FTA Elute cards according to the manufacturer’s protocol (GE Healthcare). DNA samples were diluted to 2 ng/mL. Duplicate measurements were performed in 10% of the samples to assess the internal quality of genotype data. Molecular genotyping for rs4588 (substitution of C for A), rs7041 (substitution of T for G), and rs2282679 (substitution of A for C) was performed through real-time polymerase chain reaction (PCR) (ViiA7 Real-Time Polymerase Chain Reaction System, Applied Biosystems, California, USA) using the allelic discrimination assay with TaqMan MGB primers and probes (Applied Biosystems, California, USA). BDP isoforms were constructed from the combination of the rs4588 and rs7041 polymorphisms, formally called GC1s (rs4588 CC and rs7041 GG), GC1f (rs4588 CC and rs7041 TT), and GC2 (rs4588 AA and rs7041 TT).
Statistical analysis

The Shapiro-Wilk normality test and descriptive statistics were used to evaluate the distribution of data. Results are presented as mean ± standard deviation (SD), median and interquartile range, or percentage. Non-Gaussian variables were log-transformed for statistical analysis and reported after being back-transformed into their original units of measurement. One-way analysis of variance (ANOVA) was used to compare group means. A test for linear trend was used to detect codominant effects of genotypes on DBP and 25(OH)D levels. Pearson’s chi-square test ($\chi^2$) was used to test categorical variables and the agreement of genotype frequencies with Hardy-Weinberg equilibrium. The relation of the outcome of interest (25(OH)D status) with genotypes, DBP isoforms, DBP levels, time since menopause, HOMA-IR, and estradiol was evaluated using prevalence ratios (PR) estimated by univariate Poisson regression with robust variance. A multivariate Poisson regression model with robust variance was constructed to adjust the analysis for age and BMI (model 1) and model 1 plus vitamin D supplementation (model 2). The 25(OH)D ≥20 ng/mL category was used as reference. All analyses were performed in PASW Statistics for Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA). Significance was accepted at $p<0.05$.

Results

Table 1 summarizes the clinical and biochemical profile of the 443 participants according to menopause status (13.8% premenopausal, 5.2% perimenopausal, and 81.0% postmenopausal). The peri- and postmenopausal women had significantly higher blood pressure, TC, LDL-c, and HOMA-IR, as well as lower estradiol and DBP levels, than premenopausal participants ($p<0.05$ for all variables). The mean serum 25(OH)D level in the overall sample was 22.80 ±8.32 ng/mL; 60.3% had sufficient circulating 25(OH)D levels ($\geq 20$ ng/mL), while 39.7% had deficient 25(OH)D levels ($<20$ ng/mL). The three subgroups had similar prevalence of vitamin D deficiency and circulating 25(OH)D levels (Table 1). Participants were mostly Caucasian (80%); 20% were of mixed African and European ancestry. Overall, 8.9% and 5.9% of participants were taking calcium and vitamin D supplementation, respectively, and 7.9% were on hormone therapy. PTH and calcium levels measured in a subset of 84 postmenopausal women were within the reference range [median PTH: 41.75 pg/mL (32.83–50.75); mean calcium: 9.10 ±0.33 mg/dL].

Genotype and DBP isoform frequencies of GC gene variants are shown in Table 2. Only two participants were not genotyped for SNP rs4588, and three for both SNP rs7041 and rs2282679. All three SNPs were in Hardy-Weinberg equilibrium (rs4588: $\chi^2 = 1.47$, $p = 0.23$; rs7041: $\chi^2 = 2.88$, $p = 0.09$; rs2282679: $\chi^2 = 0.17$, $p = 0.68$).

Regarding the distribution of CG gene variants according to vitamin D status, CC genotype frequencies of rs2282679 and GC2 DBP isoform were significantly higher in participants with 25(OH)D $<20$ ng/mL than in participants with $\geq 20$ ng/mL (13.9% vs. 4.9%, $p = 0.004$; and 28.4% vs. 15.0%, $p = 0.016$ respectively) (Fig 1).

Table 3 shows DBP and 25(OH)D serum levels according to genotypes of GC gene polymorphisms and DBP isoforms. The AA genotype of rs4588, CC genotype of SNP rs2282679, and the GC2 isoforms were associated with lower DBP, but no such association was found for SNP rs7041. The TT genotype of rs7041, CC genotype of rs2282689, and DBP GC2 isoform were also associated with lower 25(OH)D levels.

Prevalence ratios for 25(OH)D $<20$ ng/mL according to rs2282679 genotype, DBP isoforms, DBP levels, time since menopause, HOMA-IR and estradiol are shown in Table 4. A higher risk of 25(OH)D $<20$ ng/mL was associated with CC genotype of rs2282679 (PR 1.740; 95%CI 1.301 to 2.237; $p<0.001$), GC2 isoform (PR 1.664; 95%CI 1.165 to 2.377; $p = 0.005$),
time since menopause (PR 1.019; 95%CI 1.003 to 1.034; p = 0.016) and HOMA-IR (PR 1.018; 95%CI 1.006 to 1.033; p = 0.004). A lower risk of 25(OH)D < 20 ng/mL was associated with DBP levels (per 30 μg/mL increase in DBP: PR 0.886; 95%CI 0.796 to 0.987; p = 0.027). These prevalence ratios remained significant even after adjustment for age, BMI, and vitamin D supplementation.

Discussion

In the present study, the CC genotype of the rs2282679 SNP and the GC2 isoform of the GC gene were associated with lower DBP and total 25(OH)D levels, as well as with higher risk of vitamin D deficiency. Moreover, the prevalence ratio of vitamin D deficiency was almost twice as high in carriers of these gene variants.

Few studies have assessed the impact of GC-DBP gene polymorphisms on 25(OH)D levels or measured serum DBP concentrations in women of diverse ethnic origins at different reproductive periods. Indeed, previous studies in other women populations have shown discrepant results—a lack of association [33–35] in some cases, or conversely a relationship between GC gene polymorphisms and 25(OH)D levels [8, 11, 12, 15, 16, 36, 37]. In addition, an association of these gene with 25(OH)D levels has been observed in specific conditions, such as polycystic ovary syndrome (PCOS) [17], type 2 diabetes [18], and early breast cancer [38]. Beyond that, previous studies have reported an association between SNP rs2282679 and vitamin D...
deficiency [19, 20], and between DBP levels and its gene polymorphisms [8, 11–14], except for one study with negative results [34]. Our finding of an association between the GC2 isoform and lower DBP levels in southern Brazilian women is in line with these previous findings in other populations.

Interestingly, the distribution of DBP isoforms has been reported to vary according to distinct ethnic patterns. Black and Asian populations are more likely to carry the GC1f isoform, and only rarely the GC2, whereas whites more frequently exhibit the GC1s and GC2 isoforms [6, 7]. The present results are consistent with this observation, since our participants, who were mostly of white European descent, had a higher frequency of the GC1s isoform.

We found that DBP levels were lower in peri- and postmenopausal women than in premenopausal women. DBP synthesis in the liver is regulated by sex-steroid hormones, particularly estrogen, which stimulates hepatic DBP synthesis. Thus, during the menopausal transition and postmenopause, changes in ovarian estrogen secretion may account for lower DBP and total vitamin D circulating concentrations [6, 9]. Although our data in this sample of women with no clinical evidence of disease did not show differences in total, free, or bioavailable 25(OH)D levels between groups according to menopause status, the time since menopause was associated with a higher prevalence ratio, and DBP levels with a lower prevalence ratio, of 25(OH)D deficiency, independently of age and BMI. These data support emerging evidence regarding a positive correlation between total 25(OH)D concentrations and DBP levels [8, 9]. Indeed, around 85–90% of the circulating vitamin D pool are bound to DBP, especially the 25(OH)D form, which has higher binding affinity than 1,25-dihydroxyvitamin D [1,25(OH)2D] [6, 7].

In addition, we found a relationship between HOMA-IR and higher odds of vitamin D deficiency, even after adjustment for age, BMI and vitamin D supplementation. In fact, insulin resistance has been associated with lower circulating levels of vitamin D in women at different reproductive stages, such as after the menarche [39], during reproductive years [40], and in the pre- [41] and postmenopause [42].

Table 2. GC gene polymorphisms and DBP isoforms frequencies.

| SNP    | n (%) |
|--------|-------|
| rs4588 |       |
| CC     | 226 (51.2%) |
| CA     | 172 (39.0%) |
| AA     | 43 (9.8%) |
| rs7041 |       |
| TT     | 126 (28.6%) |
| TG     | 202 (45.9%) |
| GG     | 112 (25.5%) |
| rs2282679 |     |
| AA     | 228 (51.8%) |
| AC     | 175 (39.8%) |
| CC     | 37 (8.4%) |
| DBP isoforms |   |
| GC1s   | 110 (60.8%) |
| GC1f   | 33 (18.2%) |
| GC2    | 38 (21.0%) |

rs4588: 2 missing; rs7041 and rs2282679: 3 missing. GC1s (rs4588 = CC and rs7041 = GG); GC1f (rs4588 = CC and rs7041 = TT); GC2 (rs4588 = AA and rs7041 = TT).

https://doi.org/10.1371/journal.pone.0226215.t002

deficiency [19, 20], and between DBP levels and its gene polymorphisms [8, 11–14], except for one study with negative results [34]. Our finding of an association between the GC2 isoform and lower DBP levels in southern Brazilian women is in line with these previous finings in other populations.

Interestingly, the distribution of DBP isoforms has been reported to vary according to distinct ethnic patterns. Black and Asian populations are more likely to carry the GC1f isoform, and only rarely the GC2, whereas whites more frequently exhibit the GC1s and GC2 isoforms [6, 7]. The present results are consistent with this observation, since our participants, who were mostly of white European descent, had a higher frequency of the GC1s isoform.

We found that DBP levels were lower in peri- and postmenopausal women than in premenopausal women. DBP synthesis in the liver is regulated by sex-steroid hormones, particularly estrogen, which stimulates hepatic DBP synthesis. Thus, during the menopausal transition and postmenopause, changes in ovarian estrogen secretion may account for lower DBP and total vitamin D circulating concentrations [6, 9]. Although our data in this sample of women with no clinical evidence of disease did not show differences in total, free, or bioavailable 25(OH)D levels between groups according to menopause status, the time since menopause was associated with a higher prevalence ratio, and DBP levels with a lower prevalence ratio, of 25(OH)D deficiency, independently of age and BMI. These data support emerging evidence regarding a positive correlation between total 25(OH)D concentrations and DBP levels [8, 9]. Indeed, around 85–90% of the circulating vitamin D pool are bound to DBP, especially the 25(OH)D form, which has higher binding affinity than 1,25-dihydroxyvitamin D [1,25(OH)2D] [6, 7].

In addition, we found a relationship between HOMA-IR and higher odds of vitamin D deficiency, even after adjustment for age, BMI and vitamin D supplementation. In fact, insulin resistance has been associated with lower circulating levels of vitamin D in women at different reproductive stages, such as after the menarche [39], during reproductive years [40], and in the pre- [41] and postmenopause [42]. In women with PCOS, who usually have an unfavorable
Fig 1. GC gene genotype and DBP isoform distribution according to 25(OH)D status. Data are expressed as percentages; p value by Pearson’s chi-square test. *p = 0.004 for SNP rs2282679; **p = 0.016 for GC2 DBP isoform.

https://doi.org/10.1371/journal.pone.0226215.g001

Table 3. DBP and 25(OH)D levels according to GC gene genotype and DBP isoforms.

| SNP       | DBP (μg/mL) | B   | Linear p trend | 25(OH)D (ng/mL) | B   | Linear p trend |
|-----------|-------------|-----|----------------|-----------------|-----|----------------|
| rs4588    |             |     |                |                 |     |                |
| CC        | 202.98±28.28| -8.4| <0.001         | 23.00±8.84      | -0.6| 0.282          |
| CA        | 196.49±29.88|     |                | 23.16±7.83      |     |                |
| AA        | 183.95±36.85|     |                | 20.77±7.15      |     |                |
| rs7041    |             |     |                |                 |     |                |
| TT        | 192.96±33.41| 3.5 | 0.078          | 21.48±7.54      | 1.2 | 0.030          |
| TG        | 201.38±28.06|     |                | 23.20±8.24      |     |                |
| GG        | 199.82±30.02|     |                | 23.78±9.14      |     |                |
| rs2282679 |             |     |                |                 |     |                |
| AA        | 203.13±27.90| -9.3| <0.001         | 23.39±8.79      | -1.3| 0.034          |
| AC        | 196.41±30.04|     |                | 22.83±7.80      |     |                |
| CC        | 180.88±38.20|     |                | 19.70±7.17      |     |                |
| DBP isoforms |         |     |                |                 |     |                |
| GC1s      | 199.41±29.89| -7.7| 0.012          | 23.83±9.19      | -1.9| 0.015          |
| GC1f      | 204.83±31.58|     |                | 20.63±8.29      |     |                |
| GC2       | 180.75±37.58|     |                | 20.25±7.39      |     |                |

Data are expressed as mean ± SD. p value by linear trend test.

https://doi.org/10.1371/journal.pone.0226215.t003
metabolic profile, vitamin D levels were inversely associated with insulin resistance (measured by clamp or HOMA-IR) [43] and with metabolic syndrome and higher glucose and triglycerides levels [5]. A recent review of in vitro, animal, and human in vivo studies also underlines the association between vitamin D deficiency and cardio-metabolic variables related to insulin resistance [44]. A few studies have also reported that genetic variations in GC-DBP gene were associated with insulin resistance and normal glucose tolerance in Japanese [45] and with metabolic syndrome in PCOS women [17].

The strengths of our study include novel data on Brazilian women, a less well-represented population in studies about determinant factors of vitamin D levels. Furthermore, the sample included participants with no evidence of clinical disease, which reduces the possible interference of pathological processes in our findings. Limitations of this study include the lack of data on dietary vitamin D intake and daily sun exposure, even though it is well recognized that, at latitudes below 35°, UVB radiation is sufficient for year-round vitamin D synthesis [46].

**Conclusion**

Data from this study suggest that the CC genotype of rs2282679 and the GC2 isoform of DBP are related to lower serum DBP levels and with susceptibility to 25(OH)D deficiency in adult and postmenopausal women with no evidence of clinical disease, independently of age and BMI.

**Acknowledgments**

We thank Iriane Prado de Santis for her support with laboratory analyses.

**Author Contributions**

**Conceptualization:** Betânia Rodrigues Santos, Poli Mara Spritzer.

**Data curation:** Betânia Rodrigues Santos.

**Formal analysis:** Betânia Rodrigues Santos, Nathália Cruz Costa, Thais Rasia Silva, Karen Oppermann, Gislaine Casanova.

---

**Table 4. Prevalence ratios for 25(OH)D < 20 ng/mL according to rs2282679 genotypes, DBP isoforms, DBP levels, time since menopause, HOMA-IR, and estradiol levels.**

| Variable                  | PR (95% CI) | p value | PR (95% CI) | p value | PR (95% CI) | P value |
|---------------------------|-------------|---------|-------------|---------|-------------|---------|
| rs2282679                 |             |         |             |         |             |         |
| AA                        | 1.0         | -       | 1.0         | -       | 1.0         | -       |
| AC                        | 0.981 (0.758–1.269) | 0.884 | 0.978 (0.753–1.269) | 0.865 | 0.963 (0.740–1.254) | 0.780 |
| CC                        | 1.740 (1.301–2.237) | <0.001 | 1.738 (1.303–2.318) | <0.001 | 1.696 (1.263–2.276) | <0.001 |
| DBP isoforms              |             |         |             |         |             |         |
| GC1s                      | 1.0         | -       | 1.0         | -       | 1.0         | -       |
| GC1f                      | 1.500 (1.008–2.323) | 0.046 | 1.473 (0.978–2.218) | 0.064 | 1.486 (0.993–2.223) | 0.054 |
| GC2                       | 1.664 (1.165–2.377) | 0.005 | 1.626 (1.147–2.306) | 0.006 | 1.593 (1.120–2.265) | 0.010 |
| DBP (per 30 μg/mL increase) | 0.886 (0.796–0.987) | 0.027 | 0.876 (0.787–0.975) | 0.015 | 0.881 (0.790–0.982) | 0.022 |
| Time since menopause (years) | 1.019 (1.003–1.034) | 0.016 | 1.032 (1.012–1.053) | 0.002 | 1.033 (1.012–1.054) | 0.001 |
| HOMA-IR                   | 1.018 (1.006–1.033) | 0.004 | 1.015 (0.999–1.030) | 0.063 | 1.015 (1.000–1.030) | 0.046 |
| Estradiol (pg/mL)         | 1.001 (0.999–1.003) | 0.332 | 1.001 (0.999–1.004) | 0.405 | 1.001 (0.999–1.004) | 0.394 |

p value by univariate Poisson regression with robust variance. ¹ model adjusted for age and BMI; ² model adjusted for age, BMI, and vitamin D supplementation. DBP: vitamin D-binding protein; HOMA-IR: homeostasis model assessment index to estimate insulin resistance.

https://doi.org/10.1371/journal.pone.0226215.t004
Funding acquisition: Poli Mara Spritzer.

Investigation: Thais Rasia Silva, Karen Oppermann, Jose Antonio Magalhães, Gislaine Casanova, Poli Mara Spritzer.

Methodology: Betânia Rodrigues Santos, Nathália Cruz Costa, Karen Oppermann, Jose Antonio Magalhães, Gislaine Casanova.

Project administration: Poli Mara Spritzer.

Resources: Poli Mara Spritzer.

Supervision: Poli Mara Spritzer.

Validation: Betânia Rodrigues Santos, Nathália Cruz Costa, Thais Rasia Silva, Jose Antonio Magalhães, Gislaine Casanova.

Visualization: Betânia Rodrigues Santos.

Writing – original draft: Betânia Rodrigues Santos.

Writing – review & editing: Betânia Rodrigues Santos, Nathália Cruz Costa, Thais Rasia Silva, Karen Oppermann, Jose Antonio Magalhães, Gislaine Casanova, Poli Mara Spritzer.

References
1. van Schoor N, Lips P. Global Overview of Vitamin D Status. Endocrinol Metab Clin North Am. 2017; 46(4):845–70. https://doi.org/10.1016/j.ecl.2017.07.002 PMID: 29080639
2. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? Journal of Steroid Biochemistry & Molecular Biology. 2014; 144:138–45.
3. Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017; 18(2):153–65. https://doi.org/10.1007/s11154-017-9424-1 PMID: 28516265
4. Holick MF. Vitamin D deficiency in 2010: health benefits of vitamin D and sunlight: a D-bate. Nat Rev Endocrinol. 2011; 7(2):73–5. https://doi.org/10.1038/nrendo.2010.234 PMID: 21263437
5. Santos BR, Lecke SB, Spritzer PM. Apa-I polymorphism in VDR gene is related to metabolic syndrome in polycystic ovary syndrome: a cross-sectional study. Reproductive Biology and Endocrinology. 2018; 16(1):38–45. https://doi.org/10.1186/s12958-018-0355-9 PMID: 29669566
6. Tsupyrov O, Chen X, Hocher CF, Skoblo R, Lianghong Yin, Hocher B. Why should we measure free 25(OH) vitamin D? Journal of Steroid Biochemistry and Molecular Biology. 2018; 180:87–104. https://doi.org/10.1016/j.jsbmb.2017.11.014 PMID: 29217467
7. Bikle DD, Malmstroem S, Schwartz J. Current Controversies: Are Free Vitamin Metabolite Levels a More Accurate Assessment of Vitamin D Status than Total Levels? Endocrinology and Metabolism Clinics of North America. 2017; 46(4):901–18. https://doi.org/10.1016/j.ecl.2017.07.013 PMID: 29080642
8. Li C, Chen P, Duan X, Wang J, Shu B, Li X, et al. Bioavailable 25(OH)D but Not Total 25(OH)D is an Independent Determinant for Bone Mineral Density in Chinese Postmenopausal Women. EBioMedicine. 2017; 15:184–92. https://doi.org/10.1016/j.ebiom.2016.11.029 PMID: 27917952
9. Pop LC, Shapses SA, Chang B, Sun W, Wang X. Vitamin D-Binding Protein in Healthy Pre- and Postmenopausal Women: Relationship with Estradiol Concentrations. Endocrine Practice. 2015; 21(8):936–42. https://doi.org/10.4158/EP15623.OR PMID: 26121448
10. Kilpatrick LE, Phinney KW. Quantification of Total Vitamin-D-Binding Protein and the Glycosylated Isoforms by Liquid Chromatography-Isotope Dilution Mass Spectrometry. Journal of Proteome Research. 2017; 16(11):4185–95. https://doi.org/10.1021/acs.jproteome.7b00560 PMID: 28990783
11. Lauridsen AL, Vestergaard P, Hermann AP, Brot C, Heickendorff L, Mosekilde L, et al. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): A cross-sectional study on 595—Early postmenopausal women. Calcified Tissue International. 2005; 77(1):15–22. https://doi.org/10.1007/s00223-004-0227-5 PMID: 15868280
12. Szili B, Szabó B, Horváth P, Bakos B, Kirschner G, Kösa JP, et al. Impact of genetic influence on serum total- and free 25-hydroxyvitamin-D in humans. Journal of Steroid Biochemistry and Molecular Biology. 2018; 183:62–7. https://doi.org/10.1016/j.jsbmb.2018.05.007 PMID: 29792983
13. Carpenter TO, Zhang JH, Parra E, Ellis BK, Simpson C, Lee WL, et al. Vitamin D Binding Protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers. Journal of Bone and Mineral Research. 2013; 28(1):231–21.

14. Robinson-Cohen C, Zelnick LR, Hoofnagle AN, Lutsey PL, Burke G, Michos ED, et al. Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Clinical Endocrinology & Metabolism. 2017; 102(8):3075–84.

15. Fang Y, van Meurs JBJ, Arp P, van Leeuwen JPT, Hofman A, Pols HAP, et al. Vitamin D Binding Protein Genotype and Osteoporosis. Calcified Tissue International. 2009; 85(2):85–93. https://doi.org/10.1007/s00223-009-9251-9 PMID: 19488670

16. Santos BR, Mascarenhas LPG, Boguszews ki MCS, Spritzer PM. Variations in the Vitamin D-Binding Protein (DBP) Gene Are Related to Lower 25-Hydroxyvitamin D Levels in Healthy Girls: A Cross-Sectional Study. Hormone Research in Paediatrics. 2013; 79(3):162–8.

17. Santos BR, Lecke SB, Spritzer PM. Genetic variant in vitamin D-binding protein is associated with metabolic syndrome and lower 25-hydroxyvitamin D levels in polycystic ovary syndrome: A cross-sectional study. PLoS One. 2017; 12(3):e0173695. https://doi.org/10.1371/journal.pone.0173695 PMID: 28278285

18. Bertoccini L, Baletti D, Buzzetti R, Cavallo MG, Copetti M, Cossu E, et al. Variability in genes regulating vitamin D metabolism is associated with vitamin D levels in type 2 diabetes. Oncotarget. 2018; 9(79):34911–8. https://doi.org/10.18632/oncotarget.26178 PMID: 30405893

19. Rivera-Paredes B, Macías N, Martínez-Aguilar MM, Hidalgo-Bravo A, Flores M, Quezada-Sánchez AD, et al. Association between Vitamin D Deficiency and Single Nucleotide Polymorphisms in the Vitamin D Receptor and GC Genes and Analysis of Their Distribution in Mexican Postmenopausal Women. Nutrients. 2018; 10(9):1175–93.

20. Kwak SY, Yongjoo Park C, Jo G, Yoen Kim O, Shin MJ. Association among genetic variants in the vitamin D pathway and circulating 25-hydroxyvitamin D levels in Korean adults: results from the Korea National Health and Nutrition Examination Survey 2011–2012. Endocrine Journal. 2018; 65(9):881–91. Endocrine. 2018; 10(9):1175–93. https://doi.org/10.1507/endocrj.EJ18-0084 PMID: 29937467

21. Di Domenico K, Wiltgen D, Nickel FJ, Magalhaes JA, Moraes RS, Spritzer PM. Cardiac autonomic modulation in polycystic ovary syndrome: does the phenotype matter? Fertility and Sterility. 2013; 99(1):286–92. https://doi.org/10.1016/j.fertnstert.2012.08.049 PMID: 23028880

22. Colpani V, Oppermann K, Spritzer PM. Association between habitual physical activity and lower cardiovascular risk in premenopausal, perimenopausal, and postmenopausal women: a population-based study. Menopause. 2013; 20(5):525–31. https://doi.org/10.1097/GME.0b013e318271b388 PMID: 23615643

23. Casanova G, dos Reis AM, Spritzer PM. Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric. 2015; 18(1):86–93. https://doi.org/10.3109/13697137.2014.940309 PMID: 25017924

24. Silva TR, Spritzer PM. Skeletal muscle mass is associated with higher dietary protein intake and lower body fat in postmenopausal women: a cross-sectional study. Menopause. 2017; 24(5):502–9. https://doi.org/10.1097/GME.0000000000000793 PMID: 27922938

25. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012; 15(2):105–14. https://doi.org/10.3109/13697137.2011.650656 PMID: 22338612

26. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644 PMID: 19805654

27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972; 18(6):499–502. PMID: 4337382

28. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6):1487–95. https://doi.org/10.2337/diacare.27.6.1487 PMID: 15161807

29. Poce CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, et al. Vitamin D-Binding Protein Modifies the Vitamin D-Bone Mineral Density Relationship. Journal of Bone and Mineral Research. 2011; 26(7):1609–16. https://doi.org/10.1002/jbmr.387 PMID: 21416506

30. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology & Metabolism. 1999; 84(10):3666–72.
31. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin-d in serum and its regulation by albumin and the vitamin-d-binding protein. Journal of Clinical Endocrinology & Metabolism. 1986; 63(4):954–9.

32. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research. 1988; 16(3):1215. https://doi.org/10.1093/nar/16.3.1215 PMID: 3344216

33. Almesri N, Das NS, Ali ME, Gumaa K, Giha HA. Independent association of polymorphisms in vitamin D binding protein (GC) and vitamin D receptor (VDR) genes with obesity and plasma 25OHD3 levels demonstrate sex dimorphism. Applied Physiology, Nutrition, and Metabolism. 2016; 41(4):345–53. https://doi.org/10.1139/apnm-2015-0284 PMID: 26881316

34. Yao S, Hong CC, Bandera EV, Zhu Q, Liu S, Cheng TD, et al. Demographic, lifestyle, and genetic determinants of circulating concentrations of 25-hydroxyvitamin D and vitamin D-binding protein in African American and European American women. American Journal of Clinical Nutrition. 2017; 105(6):1362–71. https://doi.org/10.1093/ajcn/116.143248 PMID: 2842184

35. Chupeerach C, Tungtrongchitr A, Phoront B, Schweigert FJ, Tungtrongchitr R, Preuthiphan S. Association of Thr420Lys polymorphism in DBP gene with fat-soluble vitamins and low radial bone mineral density in postmenopausal Thai women. Biomarkers in Medicine. 2012; 6(1):103–8. https://doi.org/10.2217/bmm.11.88 PMID: 22296203

36. Abbas S, Nieters A, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, et al. Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Research. 2008; 10(2):11.

37. Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. American Journal of Clinical Nutrition. 2009; 89(2):634–40. https://doi.org/10.3945/ajcn.2008.26445 PMID: 19116321

38. Hattse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012; 33(7):1319–26. https://doi.org/10.1093/carcin/bgs187 PMID: 22623648

39. Ashraf AP, Huisingh C, Alvarez JA, Wang X, Gower BA. Insulin resistance indices are inversely associated with vitamin D binding protein concentrations. J Clin Endocrinol Metab. 2014; 99(1):178–83. https://doi.org/10.1210/jc.2013-2452 PMID: 24170105

40. Contreras-Manzano A, Villalpando S, García-Díaz C, Flores-Aldana M. Cardiovascular Risk Factors and Their Association with Vitamin D Deficiency in Mexican Women of Reproductive Age. Nutrients. 2019; 11(6).

41. Giovannazzo S, Alibrandi A, Campenni A, Trimarchi F, Ruggeri RM. Correlation of cardio-metabolic parameters with vitamin D status in healthy premenopausal women. J Endocrinol Invest. 2017; 40(12):1337–43. https://doi.org/10.1007/s40618-017-0707-x PMID: 28616825

42. Schmitt EB, Nahas-Neto J, Bueloni-Dias F, Poloni PF, Orsatti CL, Petri Nahas EA. Vitamin D deficiency is associated with metabolic syndrome in postmenopausal women. Maturitas. 2018; 107:97–102. https://doi.org/10.1016/j.maturitas.2017.10.011 PMID: 29169589

43. Naderpour N, Sharakae S, Abeil SK, Mousa A, Joham AE, Moran Lj, et al. Bioavailable and free 25-hydroxyvitamin D and vitamin D binding protein in polycystic ovary syndrome: Relationships with obesity and insulin resistance. J Steroid Biochem Mol Biol. 2018; 177:209–15. https://doi.org/10.1016/j.jsbmb.2017.07.012 PMID: 28734987

44. Szymczak-Pajor I, Śliwińska A. Analysis of Association between Vitamin D Deficiency and Insulin Resistance. Nutrients. 2019; 11(4).

45. Hirai M, Suzuki S, Hinokio Y, Hirai A, Chiba M, Akai H, et al. Variations in vitamin D-binding protein (group-specific component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance. Journal of Clinical Endocrinology & Metabolism. 2000; 85(5):1951–3.

46. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin-D3—exposure to winter sunlight in Boston and Edmonton will not promote vitamin-D3 synthesis in human-skin. Journal of Clinical Endocrinology & Metabolism. 1988; 67(2):373–8.